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ABSTRACT: 
Dopamine transporters (DAT) as well as other monoamine transporters are targets 
for several antipsychotic drugs of abuse thereby making them a potential target for 
regulation of neurotransmitters in the body. Cannabis Sativa is a known 
psycostimulant which contains compounds called cannabinoids (CB). CB exerts their 
effect in the body by mainly activating the CB1 receptor which is expressed 
predominantly in the central nervous system. Both dopamine (DA) and CB are linked 
to the reward system and enforcement of addictive substances. This study aims to 
investigate the effect cannabinoid have on DA transmission in differentiated PC12 
cells using a fluorescence based assay called neurotransmitter transporter uptake 
assay (NTUA). This homogenous assay uses a fluorescent false transmitter which 
mimics either NAd, DA and serotonin transporter substrate. An increase in 
fluorescence in cells indicates possible transporter activity, thereby making it 
possible to assess transporter activity by quantitative fluorescence technique. 
Differentiated PC12 cells showed increased fluorescence signal when compared to 
the undifferentiated cells. Fluorescent uptake was significantly reduced in the 
presence of the DAT blocker, GBR (100nM) and the noradrenaline transporter 
blocker, desipramine (1µM). Suggesting the fluorescent false transmitter isn’t 
specific. The cannabinoids also showed no significant effect on the fluorescent 
uptake of the cells. While PCR results showed that differentiated PC12 cells had low 
expressions of the cannabinoid receptor 1 gene (CNR1), making this cell line 
unsuitable for this cannabinoid study, however further testing is required.  
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INTRODUCTION 
Noradrenergic Transmission 
Catecholamines (CAs) include compounds with a catechol moiety and an amine 
group. The three pharmacologically important and widely distributed CAs in the brain 
are noradrenaline (NAd), adrenaline (Ad), and dopamine (DA). CAs are important 
neurotransmitters the brain and peripheral nervous system (Tsunoda, 2006). 
Compared to NAd, the distribution of DA in the brain is more restricted. It is most 
abundant in the corpus striatum, the part of the brain concerned with the 
coordination of movement. Ad on the other hand occurs in smaller amounts in the 
brain, much less than 10% of the NAd (Carlsson, 1959). 
In the late 1950s,3-hydroxytyramine (DA) was identified as a neuromodulator and it 
was also recognised as the most prominent catecholamine in the brain (Carlsson, 
1959; Missale et al., 1998). DA’s importance in neuropharmacology is due to its 
involvement in variety of functions such as neuroendocrine secretion, locomotor 
activity, feeding, emotions, learning and reward (Jaber et al., 1996). The major 
dopaminergic pathways in the brain are mesocorticolimbic, nigrostriatal and 
mesolimbic systems (Missale et al., 1998; Beaulieu and Gainetdinov, 2011). 
Dopaminergic neurons have important physiological roles in immune and 
cardiovascular functions (Jaber et al., 1996). Many disorders result from 
dopaminergic dysfunction, which is not surprising based on the various critical 
processes DA is involved in the body.  Studies show that most drugs of abuse act on 
the reward circuitry, leading to a prolonged increase in extracellular DA in the 
nucleus accumbens (NA) and other forebrain areas (Herkenham et al., 1990; Lupica 
and Riegel, 2005). 
 
Most drugs used to treat neurological disorder and addiction affect DA signalling in 
the brain. An important example is the treatment of the neurodegenerative disorder 
Parkinson’s diseases, which results from a loss of dopaminergic neurons in the 
substantia nigra (Kopin, 1993). L-dopa, a metabolic precursor of DA is used to 
improve symptoms of the disease, by helping with the local synthesis of DA and 
hence compensating for the DA lost during degeneration in the substantial nigra 
(Girault & Greengard, 2004).Other abnormal DA signalling related disorders include 
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Huntington disease, schizophrenia, depression, bipolar disorder and attention deficit 
disorder (Beaulieu and Gainetdinov, 2011). The key steps in normal 
catecholaminergic neurotransmission are shown in figure 1. 
 
 
Figure 1: Main Steps involved in Neurotransmission. Neurotransmitter is synthesized 
then stored (by vesicular neurotransmitter transporters; VNT) in the synaptic vesicles, 
and released through exocytosis. The neurotransmitter transporter (PNT) then 
removes the neurotransmitter from the synaptic cleft hence aiding uptake in pre- and 
post- synaptic neurons (Masson et al., 1999). 
 
DA is a metabolite of the amino acid tyrosine (Tyr)  and its signalling begins by the 
conversion of tyrosine to L-3-4-dihydroxyphenylalanine (L-DOPA) in the cytoplasm 
by tyrosine hydroxylase (TH, a rate limiting step), followed by decarboxylation of L-
DOPA to DA by DOPA decarboxylase (Beaulieu and Gainetdinov, 2011). 
Dopaminergic neurons lack dopamine β -hydroxylase and thus do not produce 
noradrenaline (Masson et al., 1999). DA is then transported and stored in storage 
synaptic vesicles. The proper transport and packaging of monoamines into 
specialized secretory vesicles is required to maintain homeostasis in the central 
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nervous system. The process is mediated by specific vesicular transporter: 
particularly the vesicular monoamine transporter 2 (VMAT2). VMAT2 is 
predominantly localized to the central nervous system in monoaminergic brain 
regions, where it packages free monoamines from the cytosol into small synaptic 
and dense core vesicles (Nirenberg et al., 1996). 
Dopaminergic Receptors 
After DA is released from presynaptic terminals, it interacts with and activates DA 
receptors on the pre- and postsynaptic neuron. The various actions of DA are 
mediated by specific receptors named D1 to D5. The first evidence of DA receptors 
existence in the brain was in 1972, when it was revealed that dopamine stimulates 
adenylyl cyclase (AC) (Kebabian and Calne, 1979). All DA receptors belong to a 
large G-protein-coupled transmembrane receptor family (Jaber et al., 1996). Initially, 
the two recognised classes of DA receptors were the D1 and D2 receptors, which 
respectively stimulate and inhibit AC. Gene cloning later revealed further subtypes, 
D1 to D5 (Girault & Greengard, 2004).The D1-like receptor family includes D5, this is 
mainly due to similarities in their homology and pharmacology. The D2 family 
includes D3 and D4 ; which are pharmacologically more important. Activation of D2 
receptors at a molecular level, opposes the effect of D1 receptor activation, but has a 
more synergistic action with more complex output (Missale et al., 1998). 
DA receptors are expressed in the brain in distinct but overlapping areas (Jaber et 
al., 1996). They are enriched in distinct populations of striatal neurons, although 
there is a degree of co-expression. D1 receptors are abundant and widespread in 
areas receiving a dopaminergic innervation (namely the striatum, limbic system, 
thalamus and hypothalamus), as are D2 receptors, which also occur in the pituitary 
gland (Undieh, 2010). D2 receptors are found not only on dopaminergic neurones, 
where they function as inhibitory auto-receptors, but also on non-dopaminergic 
neurons. D3 receptors occur in the limbic system but not in the striatum. Although D3 
receptors seem to play a minor role in normal circumstances, they appear to be up-
regulated in pathologic conditions, making them prime targets for drug development. 
The D4 receptor is much more weakly expressed, mainly in the cortex and limbic 
system (Jackson and Danielsson, 1994). 
                                                                                                                               MSC Pharmacology                             
13 
 
Dopamine Transporter (DAT) 
Monoamine transporters are localized on the plasma membrane of nerve terminals, 
where they are crucial for the termination of monoamine transmission and 
maintenance of presynaptic monoamine storage (Jorgensen et al., 2007). The 
neurotransmission of DA begins with its presynaptic release and interaction with 
postsynaptic receptors. DA’s reuptake is largely terminated via a sodium- chloride 
(Na+-/Cl−) dependent DAT (Gulley and Zahniser, 2003). The synaptic concentration 
of DA in the body is regulated by DAT activity; hence it plays an important role in the; 
(i) clearance and maintenance of DA homeostasis in the CNS (Ciliax et al., 
1995; Chen and Reith, 2000) 
(ii) Reduction of potential neurotoxicity from excitatory neurotransmitters 
(Nelson, 1998).  
The importance of DAT in the brain has been appreciated for some time also 
because of the intense psychomotor stimulation produced by drugsthat target and 
block DAT activity (Zahniser and Sorkin, 2004). 
Monoamine transporters are major targets for psychostimulant, anti-depressant and 
addictive drugs (Amara and Sonders, 1998). Interacting and/or binding with DAT 
protein can regulate its function.  Studies carried out with cocaine suggest that its 
effect in the brain is due to its action on dopamine transporters. Cocaine, when in 
contact with the transporter, binds and blocks dopamine transport. The 
psycholostimulant, amphetamine structurally resemble DA and thus can easily be 
transported into the cell by DAT. The regulation of the transporter by these drugs can 
have profound pharmacological and neurobiological consequences (Chen and Reith, 
2000) 
These drugs also have affinity for other Na+/Cl− dependent neurotransmitter 
transporters, which include; NA, serotonin, GABA, and amino acid transporters 
(Motenson and Amara, 2003; Zhang et al., 2009). In mammals these transporters 
have similar structure (figure 2), possessing a 12- transmembrane helices, 
connected by a single intracellular and extracellular loop, with the N- and C- termini 
located in the cytosol (Nelson, 1998; Chen and Reith, 2000). 
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Figure 2: Proposed diagram of mammalian monoamine transporters (Nelson, 1998) 
Like DAT, most members of the Na+/Cl− dependent carrier family are expressed at 
the plasma membrane, where they catalyse the accumulation of their respective 
substrates within the cell. In order to move substrate against a concentration 
gradient, dopamine transporters co-transport 2Na+ and 1Cl-ions along with substrate; 
the ions are needed to provide the thermodynamic driving force for inward flux. Thus, 
transport requires sodium and chloride and, depending on the net charge of 
substrates and ions, the process is potentially electrogenic (Motenson and Amara, 
2003). Noradrenaline is said to be co-transported with 1Na+ and 1Cl- (Nelson, 1998).  
In the past few years it has been shown that DAT can be regulated by exposure to 
DAT substrates and inhibitors, and by ligands interacting with dopamine receptors 
(Motenson and Amara, 2003; Zahniser and Sorkin, 2004). Although deletion of DAT 
has offered a powerful tool to study the transporter role in dopaminergic 
neurotransmission, more transient regulation of transporter activity is an important 
mechanism by which functional changes in the transporter can occur in the system. 
Recent studies have shown that transporter activity can be altered more persistently 
after exposure to and removal of transporter substrates and blockers. Resulting 
changes in transporter conformation and effect is either due to change in affinity of 
the transporter for dopamine, or change in the number of transporters expressed at 
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the cell surface. Interestingly, the bulk of the evidence supports the latter (Gulley and 
Zahniser, 2003). 
Given that DAT function can be modified, I wish to explore whether cannabinoids 
might do so. Such regulation could have important implications that would improve 
treatment for addiction and neurological disorders.  
What are cannabinoids? 
Cannabis sativa is a plant known for its medicinal and recreational purposes (Casu 
et al., 2003). They are bushy plants which grows wild in tropical climate. Cannabis 
plants contain many chemical compounds that differ in their pharmacological 
properties. Consumption of cannabis in different quantities either by smoking, eating 
or drinking are known to induce relaxation, euphoria, anxiety, depression and 
hallucination (Manzanares, et al., 2006). In the 1960s, the active component of this 
plant and the primary substance responsible for its psychoactive effectwas 
discovered and named (−)-trans-Δ9-tetrahydrocannabinol (Δ9-THC) (Pacher, et. al, 
2006).  Δ9-THC is present in the female plant (Freund, Katona and Piomelli, 2003). 
Cannabis contains other metabolites that are potentially of biological interest, 
including flavonoids, terpens and carotenoids (Guy, Whittle, Robson, 2004).  
Presently C. sativais recognized to contain more than 60 terpenoid compounds 
called cannabinoids (Pertwee, 2001).  
 
Cannabinoids are natural or synthetic compounds exerting their pharmacological 
effect by activating cannabinoid CB1 and/or CB2 receptors (Romero et al., 1998). The 
different types of cannabinoid are shown in figure 3. The discovery of an 
endogenous cannabinoid system in the 1990 restored interest in cannabinoid as 
medicines (Guy et al., 2004). The United States made a law allowing cannabis to be 
prescribed for medical use (Manzanares et al, 2006).  It is mainly used to relieve 
pain in cancer and AIDS patients. The principal cannabinoids found in cannabis are; 
Δ9-THC, Δ8-THC, cannabinol, cannabicyclol and cannabidiol (Alexander et al., 2009). 
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Figure 3: Showing types of cannabinoids (Marder et al., 2007). 
 
Endogenous cannabinoid system 
Endocannabinoids are lipid functional ligands of cannabinoid (CB) receptors that are 
synthesized by the body. All endocannabinoids are derivatives of poly-unsaturated 
fatty acids (Pertwee 2006; Di Marzo, et al. 1997). They are particularly well-known 
for retrograde signalling in the nervous system (i.e the endocannabinoid travels from 
postsynaptic neurons to presynaptic neurons). They are present in the brain and 
most tissues, where they regulate functions such as appetite, memory and mood. 
Howlett in the 1980s discovered the presence of G-protein coupled cannabinoid 
receptor in the brain (Manzanares et al., 2006; Howlett et al., 1988). When activated, 
they regulate most brain and body processes. This property makes them the ideal 
target for understanding and treating many diseases (Marder et al., 2007).  
In the early ninety’s, the cannabinoids type 1(CB1) and 2(CB2) receptors were cloned 
from the brain (Matsuda et. al., 1990; Munro et al., 1993). Both receptor types are 
coupled through G proteins to adenylyl cyclase and mitogen-activated protein (MAP) 
kinase.  CB1 receptors which have been the focus of most studies, are found 
predominantly in central and peripheral nerve terminals (CNS) where they mediate 
inhibition of transmitter release (Pertwee, 2006). CB2 is mainly located on tissue and 
immune cells are likely to be involved in regulating immune responses (Storr, et al., 
2004); one of its roles is to mediate cytokine release (Lutz, 2002). CB1 receptors 
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have been shown to be abundant in brain areas such as cortex, cerebellum and 
hippocampus (Manzanares et al., 2006). Dense concentrations of the CB1 receptors 
have been detected in structures involved in pain signalling (Tsou et al., 1998). 
Activation of the CB1 receptor subtype leads to inhibition of adenylyl cyclase, an 
increase in the activities of mitogen activated protein kinase (MAPK), and regulates 
ion channels (increases and decreases K+ and Ca2+ conductance respectively). 
Cannabinoid receptors are frequently located presynaptically and when activated 
induce suppression/inhibition of neurotransmitter release (Howlett, 2004; Pertwee, 
1999). Cannabinoid inhibits the release of many neurotransmitters including DA, NA, 
GABA, acetylcholine and L-glutamate (Manzanares et al., 2006). These 
endocannabinoids along with their receptors constitute the 'endocannabinoid system' 
(Pertwee 2006).  
Endogenous ligands for cannabinoid receptors have also been identified: 
anandamide (arachidonylethanolamide, AEA) and 2-arachidonyl glycerol (2-AG). 
Anandamide was the first endocannabinoid to be discovered and was isolated from 
porcine brain (Devane et al., 1992). It is enzymatically synthesized in the brain areas 
involved in movement, thoughts and memory (Manzanares et al., 2006). It binds 
primarily to CB1 receptors, and it has the same pharmacological activity as Δ
9 –THC, 
but is less potent. Both in vivo and in vitro tests have confirmed the similarity of 
actions between anandamide and cannabinoids in the CNS and peripheral tissues 
(Di Marzo, 1997; Freund et al., 2003). All endocannabinoid including anandamide 
are highly lipophilic and are known to be membrane bound.  Hence they can diffuse 
and interact with membrane bound enzymes and receptors. They are also known to 
diffuse into the cytoplasm, where they are transported by a saturable, high affinity 
anandamide transporter. This process which is facilitated by fatty acid hydrolase, 
leads to an action on the presynaptic cannabinoid receptor. Anandamide is 
synthesized on demand in cell membranes from phospholipid precursors in response 
to a rise in increase in the cytoplasmic calcium store (Christie, 2011).  
2-arachidonyl glycerol is more abundant and binds to both CB1 and CB2 receptors. 2-
AG is synthesized, mainly in the neurons, in two possible ways. Firstly a hydrolysis 
reaction of membrane phospholipids mediated by Phospholipase C (PLC) to produce 
1,2-diacylglycerol (DAG) which is converted to 2-AG by diacylglycerol lipase, figure 
4. Secondly, 2-AG can be synthesized by the hydrolysis of lysophospholipid to 2-AG 
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by a lyso-PLC activity (Freund et al., 2003). In the body these endocannabinoids are 
“produced only on demand” rather than stored in vesicles (Di Marzo et al., 1997). 
Once in the cell these substances are hydrolysed through a reaction is catalysed by 
fatty acid amide (FAAH), which is found in both neurones and in some tissues 
(Pertwee, 2001). 
 
Figure 4: illustration of the possible mechanism of  anadamide and 2-
arachidonoylglycerol formation (2-AG formation. PE, phosphatidylethanolamine, 1,2-
diacylglycerol lipase; DGL, 1,2-diacylglycerol lipase;  PI, phosphatidylinositol; PLA1, 
phospholipase A1 PLC, phospholipase C;DAG, 1,2-diacylglycerol. (Freund et al., 
2003). 
 
Cannabinoids and Dopamine 
Dopaminergic neurotransmission is critical in the reinforcing properties of addictive 
substances. Most drugs of abuse increase extracellular DA levels through an action 
on axon terminals of the DA neurons, located in an area of the limbic region known 
as the ventral tegmental area (VTA). The dopaminergic neurons in the VTA are the 
primary source of DA in the forebrain (Wise, 2004; Lupica and Riegel, 2005). 
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Cannabis is one of the most frequently abused drugs and its consumption affects a 
variety of neurotransmitter release (French, 1997). DA happens to be one of the 
neurotransmitters implicated in the central nervous system effect that follow 
cannabinoid administration. Such behavioural effects seen after cannabinoid 
administration are particularly associated with the actions ofΔ9-THC (French, 1997). 
Psychostimulants as well as cannabinoids increase DA function in the nucleus 
accumbens (NAc, located in the VTA) through the inhibition of DAT that is located on 
the axon terminal (Wise and Bozarth, 1987). The magnitude of DA increase depends 
on the strain and genetics of the rats assessed (Gardner, 2005; Chen et al., 1991).  
Studies have shown that rats pre-treated with the CB1 receptor agonist, WIN55, 212-
2 showed an increased mesolimbic DA concentration (Oleson and Cheer, 2012). 
The same result was recorded with small doses of cocaine and nicotine in the 
nucleus accumbens of a rat. Cannabinoid receptor antagonists such as Rimonabant 
can reduce the self-administration of, and craving for, several commonly addictive 
drugs by blocking the effects of endogenously released cannabinoid molecules 
(endocannabinoids) that are released in an activity- and Ca2+-dependent manner 
from mesencephalic dopamine neurons. Despite the mechanism of their actions, 
rimonabant inhibited the DA in each case (Cheer, et al., 2007; Herkenham et al 
1990). It is hypothesized that, through the antagonism of cannabinoid CB1 receptors 
located on inhibitory and excitatory axon terminals targeting the midbrain DA 
neurons, the effects of the endocannabinoids are blocked (Romero et al., 1998).  
Given that cannabinoids and dopaminergic function are both important for reward, it 
is useful to explore how these two systems interact presynaptically and to investigate 
the effect cannabinoid would have on DAT function through a cellular imaging 
method. Given this, we need to have an efficient method to monitor DA transporter 
function. The methods mostly used for measuring transporter function are 
biochemical uptake assays, micro-dialysis and electrophysiological recording of 
transport associated current. In this study a Neurotransmitter transporter uptake 
assay was the method used to monitor DAT activity.  
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Neurotransmitter Transport Uptake Assay (NTUA): 
This assay uses a fluorescent transporter substrate to detect and measure 
neurotransmitter transporter rate.  The fluorescent compound mimics serotonin (NE), 
NAd and DAT substrates and hence can be transported into the cells through such 
transporters, resulting in an increased fluorescence signal, figure 5. The increased 
fluorescence offers the possibility to assess transport activity by quantitative 
fluorescence techniques (Jorgensen et al., 2007).  It can also be used to: 
 label catecholamine-containing vesicles 
 screen for live-cell kinetic uptake of neurotransmitters, hence being able to 
monitor real time changes in transport function and regulation 
(Moleculardevices.com) 
 
 
 
Figure 5: Schematic illustration of the Principle behind NTUA (Jorgensen et al., 2007). 
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The ability to monitor the uptake of these neurotransmitters is important to better 
understand diseases that affect brain function. The results from this study may help 
further development of pharmacological agents to improve patients with disorders 
linked to dopaminergic transmission such as Parkinson’s disease, depression and 
even give us insight on a cellular level of addictive effect of cannabis. 
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Aims and objective 
2.1 Aims 
   To investigate the effect of cannabinoids on DAT function 
2.2 Objectives 
1. Culture cells – To optimise the cell culture conditions to maximise DAT function in 
a cell type that expresses CB1 receptors. 
2. To establish a viable and reproducible method for monitoring NTUA under a 
conventional fluorescence microscope. 
3. To test the NTUA specificity– to determine which transporters actively transport 
the fluorescent substrate into the cell lines. 
4. To test and characterize the effect of cannabinoids on DAT function. 
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HYPOTHESIS 
Cannabinoids are known to inhibit the release of variety neurotransmitters and also 
inhibit electrical activity by a depolarisation. With knowledge of this, it’s safe to 
hypothesize that in the presence of CB1 agonist there should be a noticeable drop in 
the cells fluorescence signal when compared to the control. 
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3. Materials and Method 
For the purpose of this study, this assay has been carried out using cell lines which 
synthesise catecholamine (specifically DA) and express catecholamine transporters. 
For this study BE-(2)-M17 cells and PC12 cells were used. 
3.1. Cell Culture 
Culture methods for these cell lines, and methods to induce their differentiation, are 
already established for both of the cell lines used in this study. However my initial 
effort is to investigate optimum methodology for culturing of each of the cell lines 
given the aims of the study. 
3.1.1. BE-(2)-M17 
Cells were maintained in Optimem cell culture media (Invitrogen), diluted with 10% 
foetal bovine serum (FBS; Invitrogen) and 50µg/ml of penicillin/streptomycin (Sigma-
Aldrich) in the final volume. Frozen aliquots of cells were thawed and their cryogenic 
medium replaced with fresh warm media. Thereafter, medium was replaced 2-3 
times per week at even intervals. More frequent media changes allowed faster 
growth.  
Cells were kept in 25cm2flasks and were stored at 37⁰C in a humified environment 
consisting of 5%CO2 and 95% air. Cells were passaged when they become more 
than 70% confluent. Cells were maintained at a density no greater than 
500,000cells.ml-1, and media was changed a minimum of 3 times per week. When 
passaging BE-(2)-ME17 cells, old media was removed and replaced and gently 
washed with warm Dulbecco’s phosphate buffered saline (DPBS; Sigma-Aldrich). 
DPBS was then removed and replaced with 1ml of trypsin (Invitrogen). After a few 
minutes cells were checked under the microscope to ensure that they had been 
separated from the culture surface. Cells were then transferred to a falcon tube and 
centrifuged, spinning the cells at 1000-1200 rpm for about 30s. A pellet formed at the 
bottom and the old medium was discarded without disrupting the pallet. Cells were 
then re-suspended with fresh medium, pipetting vigorously until no clumps or cluster 
of cells was observed. The cells were then transferred to a new culture flask and 
returned to the incubator. 
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3.1.2. PC12 CELLS: 
Rat adrenal phaeochromocytoma (PC12) cells were grown in 25cm2 tissue culture 
flask in RPMI 1640 (+glutamax) cell culture media (Invitrogen) supplemented with 
10% horse serum (HS, Invitrogen), 5% FBS and 50µg/ml penicillin/streptomycin 
(Invitrogen) .The cells grew quickly, with the number doubling every two days and 
passaged twice a week. PC12 cells were passaged by breaking clumps of cells in 
the culture flask and transferring to a falcon tube for centrifuge. Cells were spun at 
800RPM for 5mins. After the pellet formed, the old medium was discarded without 
disturbing the pellet. The new medium was then added, before transferring the cells 
to a new flask. They grew satisfactory in suspension in the culture flask. 
For experiments, cells were cultured on poly-l-lysine (Sigma-Aldrich, 0.1mg/ml) 
coated 13mm sterilized glass coverslips at a density of 10,000 cells per coverslip. 
Coverslips were sterilized by dipping in 70% ethanol and allowed to dry. Poly-l-lysine 
or collagen (Sigma-Aldrich, 40µg/ml) solution was prepared using with filtered 
distilled water (1:5dilution). Coverslips were coated in the appropriate cell adherent 
reagent and left to dry. Once the coverslip had dried, cells were pipetted (approx. 
50,000cells) onto the surface of the coverslip and placed in the incubator for a few 
hrs. Once cells were settled, the coverslips were flooded with warm medium to a 
volume of 1-1.5mls. The cultures were ready to use the day after culturing. Only 
coverslips on which the cells appeared flattened and adherent to the coverslip were 
used for experiment.  
For the differentiation protocol, PC12 cells were plated down onto a coverslip coated 
with human collagen 40µg/ml and completely removed from RPMI culture media. 
RPMI media was replaced with serum-free Delbecco’s Modified Eagle Medium 
(DMEM; Invitrogen) with the addition of 1% HS, 1% Penicillin/Streptomycin and 
100ng/mL of nerve growth factor (NGF; from Sigma-Aldrich). Cells were fed this 
every day for 7 days until the day of experiment (following a protocol from 
hopkinsmedicine.org). All cell culture procedures were carried out in a sterile culture 
hood (Courtesy of Prof Ann Logan’s laboratory). On the day of each experiment, a 
cover slip with cells was taken to the imaging setup and perfused with physiological 
saline solution (PSS; refer to table 1). Before commencing any experiment, perfusion 
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time was noted before the addition of any drug (based on a protocol used by Dr P. 
Sidaway (personal communication). 
3.2. Physiological Saline Solution (PSS) 
Table 1: The salt composition of PSS in 1litres 
Salt Molecular 
weight(g/mol) 
Concentration 
(mM) 
Volume or mass 
required to make 
1L of solution 
CaCl2 110.98 1.8 1.8mL 
MgCl2 95.211 1.3 1.3mL 
Glucose 180.16 5 0.901g 
NaCl 58.44 130 7.592g 
KCl 74.55 5 0.373g 
HEPES 238.3 20 4.766g 
EDTA 368.4 1 0.368g 
*pH was adjusted to 7.4 by the addition of NaOH. Molarity of CaCl2 and MgCl2 
is 1M. 
3.3. Live cell Imaging 
Cells were mounted on a Sylgard-lined organ bath and were perfused with warm 
(32-37⁰C) physiological solution (Table 1). Using a Cairn Opto-LED light source 
(Cairn imaging, Kent UK), using the NTUA cells were excited at 405nm and emitted 
at 520nm. Cells were picked at random and images were taken with an Olympus 
BX51W1 epifluorescence microscope (Olympus, southern UK) attached to an Orca 
CCD camera (Hamamatsu photonics, Welwyn Garden city, UK). Specific dilutions of 
the NTUA solution were prepared with PSS and loaded onto the cells; images taken 
prior to the addition of NTUA fluorescence substrate were used as control. 
3.4. Drugs Preparation 
NTUA Kit (MDS Analytical technologies, Berkshire UK) was diluted in PSS (10mL 
per unit) to make stock solutions and stored in 200µl aliquotsat -20⁰C.Stock was 
further diluted on the day of experiment to 1:100 or 1:10 with PSS. GBR 12909 
hydrochloride was dissolved in dimethyl sulfoxide (DMSO; Tocris Bioscience, Bristol 
UK) to a stock concentration of 1mM and stored in the -20⁰C freezer. On the day of 
experiments, dilutions were made using PSS to 100nM., Desipramine was diluted 
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with PSS to 10mM aliquots and stored in the -20⁰ freezer. On the day of experiments 
PSS was further used to dilute desipramine to 1µM for studies.  Ethanol was used to 
dilute CB1 agonist ACEA to 13.6mM and stored in the -20⁰freezers. On the day of 
studies, it ACEA was further diluted to a working concentration of 100nM.  
3.5. Image analysis 
Image analysis from digital fluorescence micrographs were performed using Image J 
version 1.44 analysis software (http://rsb.info.nih.gov/ij/). Cells were randomly 
selected, number of cells (n) = 4-13 cells. For NTUA uptake measurement’s a region 
of interest was drawn around the cells from the bright field image stack. For 
subsequent images stacks, the slice on which this segment was in focus was 
identified. The region of interest was restored and automatically fitted to the terminal 
(using an algorithm based on highest local fluorescent signal), then the mean 
fluorescent signal from this ROI was measured.  
3.6. Total RNA extraction and quantitative real-time PCR (q-PCR) 
To determine if the PC12 cells as well fresh brain tissue from rat expresses the gene 
encoding the CB1 receptor (Cnr1), q-PCR was carried out: PC12 cells were 
differentiated for 7days and total ribonucleic acid (RNA) was extracted on the 7th day 
from frozen tissue samples (rat cortex and brain stem)  and differentiated PC12 cells 
then stored in -20⁰C until use. RNA was extracted from the samples as follows; each 
sample was incubated in 1ml of Trizol reagent for 5mins at room temperature. 0.2ml 
of chloroform was added to each samples, then mixed carefully and centrifuged for 
5mins at 4⁰C at 12,000 rpm. Afterwards the colourless aqueous phase (~60% of 
TRIzol) formed after centrifuge was transferred to a fresh tube. 500µl of 70% ethanol 
was added to the lysate (colourless aqueous phase) and mixed properly. The 
samples were then transferred to RNeasy mini column and centrifuged for 15s at 
800 rpm. The flow through was discarded, before adding 700µl of Buffer RW1 to the 
RNeasy column and proceeded to centrifuge to wash the RNA in the column. 500µl 
of buffer RPE, whose main composition is ethanol and used for washing membrane 
bound RNA. Was added to the RNeasy column and centrifuged (this step was 
repeated twice). After the second repeat, the RNeasy silic-gel membrane was dry, 
and then transferred to a new tube where 40µl of RNase free water was added 
directly into the silica gel membrane was dried, and centrifuged for 1min at 800 rpm 
to elute. The eluted RNA (about 2µg) was stored at -20⁰Cuntil used (White, 2005).  
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cDNA was transcribed from the total RNA isolated from each sample (differentiated 
PC12 cells, slice of rat cortex and brain stem) using the manufacture’s instruction on 
the kit (high capacity cDNA kit, Life technologies). The amount of cDNA in each 
sample was calculated using a Nano Drop ND 1000 spectrophotometer. The Rattus 
norvegics cannabinoid receptor 1 [Cnr1, containing TaqmanProbe (FAM) primer 
sequences used were as follows: 
 forward 5’-ggacatggagtgctttatgattc-3’  
 Reverse 5’gagggacagtacagcgatgg-3’ (Pubmed - NM_012784.4).  
The expression of housekeeping gene Rat glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) containing TaqmanProbe (VIC) [Catalogue No 4352338E] 
was used as control. qPCR was performed with the 7500 fast real time PCR system 
(Applied Biosytems CA, USA).The PCR reaction mixtures were 20µl final volume in 
each well. Each reaction well contained 16µl of Taqman PCR (Applied Bisoystems 
CA, USA) master mix containing either Cnr1 or rat GAPDH (for control wells), 4µl of 
sample or water (for blank wells) in the desired wells. qPCR was repeated in 
triplicate for each sample.Thermal cycling conditions were 2mins at 50⁰C, required 
for optimal uracil-N-glycosylase (UDG) enzyme activation; 10mins at 95⁰C was to 
activate the AmpliTaq Gold DNA polymerase. Further incubated for 40cycles at 95⁰C 
for 15s, this is to denature the DNA and 60⁰C for 1min to anneal/extend the DNA. 
The thermal cycler was set with the following incubation conditions: 2 min at 50 °C to 
allow the activation of the uracil-N-glycosylase (UNG) enzyme, an incubation step for 
10 min at 95 °C to denature the UNG enzyme and activate AmpliTaq Gold 
polymerase, and 40 cycles at 95 °C for 15 s, 58 °C for 30 s and 60 °C for 30 s. All 3 
runs were conducted on different days using the same qPCR machine. Each 
condition was repeated in triplicate. 
3.7. Plate reader 
This was carried out using the Synergy HT Multi Detection Reader (BioTek, 
Winooski, VT). Fluorescent false transmitter uptake by PC12 cells was investigated 
using a fluorescence plate reader. PC12 cells were differentiated in a 96 well plate 
for 7days. On the 7thday cells in wells were incubated in either NTUA (1:10) , NTUA 
(1:10) in the presence of GBR(100nM), NTUA(1:10) + ACEA(100nM), NTUA(1:10) + 
ACEA(100nM) +AM281(100nM) or NTUA(1:10) + AM281(100nM).Fluorescence 
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readings were taken every 5mins for 30mins. There were hence 5 separate 
conditions and 5wells for each condition. Set to 485/20 excitation filter and 525/20 
emission filter, with sensitivity setting of 70. Parameters were set using the KC4 Data 
Analysis software (BioTek, Winooski, VT). 
3.8. Statistical analysis 
Each value is the mean value of the fluorescence signal in independent experiments 
5 -7 independent experiments were carried out. Normality was tested using 
D’Agustino-Pearson omnibus test. Statistical significance for comparisons among 
groups was determined using unpaired student t-test for sets of data which passed 
the normality test. While a Mann-Whitney test was carried out for sets of data which 
failed the normality test. All statistical analysis were carried out using the software 
Graphpad Prism6 (GraphPad Software, San Diego, CA, USA).For multiple groups 
one way ANOVA was carried out. Where P< 0.05 is considered statistically 
significant. See Appendix for more details. 
*NOTE from now on NTUA kit content would be referred to as ‘florescent false 
transmitter* 
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4. Result 
4.1. NTUA labelling 
In order to optically monitor DAT rate, NTUA kit was used. The kit contains a 
fluorescent dye which serves as substrate for either DA, NAd and NE transporters. 
This assay was used in cells expressing human DAT. Studies were initially carried 
out with fluorescent false transmitter (1:100 dilution) on BE-(2)-ME17 cells. These 
cells were found to have weak uptake of the fluorescent false transmitter. Due to this 
the concentration of NTUA was then increased to 1:10 dilution, but still the cell 
showed weak uptake of the fluorescence substrate (fig. 9). This resulted in a 
decision to change to a different cell line. The PC12 cell line was picked for this 
study not only due to its availability but also it richly expresses DAT (Melikian and 
Buckley, 1999). These cells grew in small clusters, much smaller than the BE-(2)-
ME17 cells. Figure 6 below shows a typical bright field microscopy image of 
differentiated PC12. Cells are clearly visible with processors and visible vesicles. 
 
Figure 6: A typical bright field image. (Scale bar = 10µm). 
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4.2. BE-(2)-M17 cells 
M17 cells were plated down on coverslip coated with poly-l-lysine and then kept in 
culture media in the incubator a day before the actual day of study. On the day of 
study, each coverslip was taken out of the culture media and placed in water bath 
where cells would be perfused with PSS. 
Bright field images were always taken every 10minutes before fluorescent images 
were taken (Fig. 7). This was to enable focusing and analysing using ImageJ 
software. The content, shape and location of the cells were very visible in the bright 
field images. 
4.2.1. Fluorescent false transmitter Uptake in BE-(2)-ME17 cells: After perfusing cells 
with PSS for 10mins, cells were exposed to the fluoresent false transmitter (1:10) for 
60mins; images were taken every 10mins. Images taken with the light emmiting 
diode (LED) prior to the addition of the fluorescent false transmitter, control images 
was taken, 0mins. Figure 7 shows LED images taken at 0mins, 30mins and 60mins. 
After addition of the fluorescent false transmitter(1:10) cells are observed to exibit an 
increase in fluorescence at this stage when compared to the control image(0mins) At 
30mins and 60mins cells show increase in fluoresence signal, 60mins showing more 
fluorescence than other times.  
Figure 7: Fluorescent false transmitter uptake in ME17 cells. Showing Fluorecence 
signal at 0mins, 30mins and 60mins.  (Scale bar = 10µm). 
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4.2.2. Fluorescent false transmitter Uptake in BE-(2)-ME17 cells in presence of GBR 
12909 (100nM): GBR 12909, a dopamine transporter blocker was diluted with PSS to 
100nM and cells were perfused with the solution for 20mins. After perfusion cells 
were exposed to the fluorescent false transmitter (1:10), diluted with PSS and GBR 
(100nM) solution. Images were taken every 10mins for 60mins (Fig. 8). 
 
Figure 8: ME17 cell uptake of fluorescent false transmitter in presence of dopamine 
transporter blocker GBR (100nM). Showing fluorescence images at 0mins, 30mins and 
60mins respectively.  The bright object seen here is debris which was close to the 
cells, but it remained constant throughout the experiment and it wasn’t included in 
the analysis. Scale bar = 10µm. 
In the presence of GBR, cells show steady, but weak uptake of the fluorescence 
false transmitter. An increase in fluorescence signal is detected from the start to end 
point (fig. 8 & 9). Below is the graphical representation after analysing the above 
experiment showing fluorescence false transmitter in the presence and absence of 
GBR (100nM) in BE-2-M17 cells. Figure 9, shows a time dependent increase in 
uptake of fluorescence transmitter. However in the presence of GBR, cells showed a 
reduced uptake of transmitter, when compared to the transmitter alone. At 10mins 
there was a drop in fluorescence of the cells exposed to the fluorescent false 
transmitter alone. No significant reduction in fluorescence signal in the presence of 
GBR when compared to its absence was observed.  
If the fluorescence false transmitter is a DAT substrate, GBR 12909 should inhibit its 
uptake, hence little or no fluorescence should be detected in this case. However M17 
cells in general during the course of this study, showed weak and inconsistent 
uptake of the fluorescence false transmitter. 
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Figure 9: Graph showing fluorescent false transmitter uptake in BE-(2)-ME17 cell line 
and also its uptake in the presence of the GBR 100nM. Unpaired Student t-test, 
P>0.05, measuring the change in end point. Data points are presented as mean ± S.E. 
Nc= 6-8 cells. 
 
 
4.3. PC12 Cells 
It was observed that PC12 cells adhered poorly to plastics, therefore cells needed 
higher concentration of poly-l-lysine. Once perfusion was turned on during 
experiments cells were easily washed away. This shows that concentration level of 
poly-l-lysine used was not adhesive enough. Although the concentration of poly-l-
lysine was increased a number of times, the result remained the same. Therefore 
collagen was used to coat coverslips to enable cells to adhere to coverslips. 
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4.3.1. Differentiation 
Undifferentiated cells appeared small and rounded. The first set of PC12 cells 
differentiated showed no neuritis out growth during the differentiation period. It 
became necessary to purchase a new NGF for the study. Thereafter 7days of 
incubating PC12 cells in DMEM containing 100ng/mL NGF, cells were seen to stop 
proliferating, they appeared flattened, larger body mass with continuous extension of 
neuritis, (Fig 10). 
Figure 10: Differentiated cell image. Cells in the absent of NGF appear rounded, small 
and no visible neuritis or processors. Second image shows cells on the 7th day after 
the addition of NGF. Cells appear to have larger cell bodies with extended processors. 
(Scale bar = 50µm) 
4.3.2. Fluorescent false transmitter Uptake in PC12cells: 
On the day of experiments, cells were perfused in PSS for 20mins before directly 
adding the fluorescent false transmitter (1:10). In initial experiments, PC 12 cells 
showed weak uptake of NTUA, so the cells were differentiated and their uptake was 
compared. Control images were taken prior (all images at 0mins are control) to 
addition of the false transmitter, whilst on addition of the drug readings were taken 
every 5mins for duration of 60mins before washing out with PSS for 30minutes. 
Before addition of the fluorescence transmitter (0mins) the nucleus and vesicles 
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were visible, after the addition of false transmitter, the vesicles of the cells became 
more prominent and punctuate (Figure 11). It was observed that in the differentiated 
cells the processors do not take up the fluorescent false transmitter (figure 12).  
 
Figure 11: images of NTUA in undifferentiated PC12 cells at different times ; 0mins –
before addition of NTUA to the cells, 30mins, 60mins after addition of fluorescent 
false transmitter ; 90mins after perfusing the cells with PSS(washout). Scale bar = 
10µm. 
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Figure 12: Showing images of uptake of the fluorescent false transmitter in 
differentiated PC12 cells at different time; 0mins (control), 30mins, 60mins after 
addition of the false transmitter; 90mins after washing the drug out of the cells with 
PSS (Scale bar = 10µm). 
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Figure 13: Graph showing effect of the fluorescent false transmitter (1:10) over time 
on undifferentiated and differentiated PC12 cells. A time dependent uptake of the 
fluorescence neurotransmitter transporter substrate was observed in both the 
differentiated and undifferentiated cells. After 60mins, the cells were perused with 
PSS (washout) for 30mins, the fluorescent labelling gradually reduced. *P<0.05; Nc= 
6-12cells. 
 
There was an increase in fluorescence signal in both differentiated and 
undifferentiated PC12 cells upon addition of the fluorescent false transmitter (1:10). 
However, the differentiated cell type showed a greater fluorescent signal; hence it 
had a greater uptake of the fluorescent transmitter. A significant increase in 
fluorescence signal was detected in all experiments carried out on the differentiated 
cells when compared to the fluorescence signal in the undifferentiated cells (P< 0.05, 
Fig. 13 and 14). Fluorescence signal in both cells dropped during washout with PSS.  
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Figure 14: Result of all experiments carried out on undifferentiated and differentiated 
PC12 cells. This shows and compares the fluorescence signal after the addition of 
fluorescence false transmitter (1:10) in undifferentiated and differentiated PC12 cells 
(Mann-Whitney test ****P<0.0001, N=6). 
 
4.3.3. Fluorescent false transmitter uptake in differentiated PC12 cells in the presence 
of DAT blocker: 
To determine if the increase in fluorescence was due to uptake through DAT, the 
cells were pre incubated with GBR 12909, a DAT blocker (100nM). Figure 15 shows 
the image of the uptake in differentiated cell without the blocker GBR 12909. Figure 
16 shows uptake of  the fluorescent false transmitter by differentiated cells in the 
presence of GBR 12909. After incubation of PC12 cells in GBR for 20mins, perfusion 
was stopped and a control image was taken (0mins). Thereafter, the cells were 
exposed to the fluorescent false transmitter (1:10) and images were taken every 
10mins. Both conditions showed increased fluorescent signal when compared to the 
control. However when compared, there was reduced signal in the presence of GBR 
(Figure 16). Upon return to PSS for 30mins, fluorescence signal dropped gradually, 
(figure 17). 
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Figure 15: Showing images of fluorescent uptake in differentiated PC12 cells at 
different times 0mins, 30mins, 60mins and at 90mins after perfusing the cells with 
PSS (washout). (Scale bar = 10µm). 
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Figure 16: Fluorescence image showing change in fluorescent signal in the presence 
of GBR (100nM). Image shows cells prior to exposure of fluorescent false transmitter 
(0mins), after addition of fluorescent transmitter at 30mins and 60mins. The drug was 
washed off the cells with PSS for 30mins. The last frame was taken 90mins after the 
start of the experiment. (Scale bar = 10µm). 
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Figure 17: Graph demonstrating the increase in fluorescence signal in differentiated 
PC12 cells in the presence of GBR (100nM). Indicating the 60mins incubation period 
and 30mins washout periods. Data points are presented as mean ± S.E.M, P= <0.05,  
Nc = 5-6 cells (see Appendix for raw data). 
 
GBR 100nM significantly reduced the uptake of fluorescent transmitter in the 
differentiated cells when compared to GBR absence (Fig. 17 & 18). GBR (100nM) 
didn’t completely block fluorescent uptake in the cells. Fluorescent intensity was 
seen to increase with time but having low signals when compared to control. Result 
of all studies carried out showed GBR significantly lowered the uptake of NTUA in 
PC12 cells (Fig. 18). 
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Figure 18: Plot of fluorescent transmitter uptake for all individual studies carried out 
on PC12 cells in the presence and absence of GBR (100nM). For the GBR study cells 
were incubated in GBR for 20mins before proceeding to expose the cells to the 
fluorescent transmitter (NTUA) (Mann-Whitney test ****P<0.0001; N=5). 
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4.3.4. SPECIFICITY: fluorescent false transmitter Uptake in Differentiated PC12 cells in 
the presence of DESIPRAMINE (1µM) 
To determine if the increase in fluorescence was due to uptake of fluorescent false 
transmitter by other catecholamine transporter, studies were carried out on 
differentiated PC12 cells in the presence of noradrenaline transporter inhibitor, 
desipramine (IµM). Cells were pre-incubated in desipramine (1µM) for 20mins. After 
which control images were taken (0mins) before cells were exposed to the false 
transmitter (1:10), pictures were taken every 10mins. Figure 19 below is the images 
taken of cells in the exposed to the fluorescent false transmitter alone. While figure 
20 shows the uptake in the presence of desipramine. 
 
Figure 19: Images showing fluorescence uptake in differentiated PC12 cells. It shows 
theres an increase in fluorescence signal in the PC12 cells from 0mins (before 
exposure NTUA) to 30mins and at 60mins. (Scale bar = 10µm). 
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Figure 20: Showing increase in fluorescence signal (NTUA uptake) in PC12 cells in the 
presence of desipramine (1µM) at different times; 0mins, at 30mins and at 60mins. 
Scale bar = 10µm. 
 
 
                                                                                                                               MSC Pharmacology                             
45 
 
 
Figure 21:Graph showing fluorescence signal in differentiated PC12 cells during 
exposure NTUA and NTUA in the presence of desipramine. Following exposure to 
NTUA (1:10) a time dependent uptake of the fluorescence neurotransmitter 
transporter substrate was observed in both conditions. Data points are presented as 
mean ± S.E. (Student’s unpaired t-test P<0.05. Nc=4-6) 
Cells were seen to gradually increase in fluorescence after exposure to NTUA (1:10) 
in the presence and absence of desipramine. However, cells that were pre-incubated 
with desipramine showed a lower fluorescence uptake. Figure 22, shows a 
compilation of fluorescence uptake in all experiments. A non-significant reduction in 
fluorescence signal in presence of desipramine when compared to the control was 
observed (*P>0.05). 
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Figure 22: Result of all experiments carried differentiated PC12 cells in presence of 
desipramine. This shows and compared the relative increase in fluorescence signal 
(NTUA, 1:10) in differentiated cells, in the presence and absence of desipramine. 
(Mann-Whitney test **P = 0.00014; N= 5). 
 
4.3.5. Effect of cannabinoid (CB1) receptor agonist ACEA, on the uptake of the 
fluorescent false transmitter in differentiated PC12 cells: In other to determine the 
role cannabinoids play in DA transport (fluorescence signal of the cells), CB1 
selective agonist ACEA (100nm) was tested in cells. Control studies were carried, 
fluorescent uptake in differentiated cells. Followed by studies in the presence of the 
agonist, ACEA (100nM); cells were pre incubated in ACEA (100nM) for 20mins, 
afterwards the fluorescent false transmitter was added to the cells for 60mins. 
Images were taken every 10mins, see figure 23 and 24.  
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Figure 23: Shows fluorescence signal in the differentiated PC12cells at different time 
intervals; 0mins, 30mins and at 60mins. Scale bar = 10µm. 
 
Figure 24: Shows fluorescence signal in the presence of ACEA (100nM) in the 
differentiated PC12 cells at different time intervals 0mins, 30mins and at 60mins. 
Scale bar = 10µm Scale bar = 10µm. 
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Figure 25; Graph showing fluorescence signal in differentiated PC12 cells during 
exposure NTUA and in presence of the CB1 agonist ACEA. Data points are presented 
as mean ± S.E. (Student’s unpaired t-test P>0.05; Nc = 5-6) 
Following exposure to the fluorescent flase transmitter (1:10) a time dependent 
uptake of the fluorescence neurotransmitter transporter substrate was observed in 
the cells (fig. 25). There was no significant difference in fluorescence signal in the 
cells pre-treated with ACEA compared to the control (N= 6; Fig, 26). 
 
Figure 26: Result of all experiments carried out on the uptake of fluorescent false 
transmitter (1:10) in the presence of ACEA in differentiated PC12 cells. It compared 
the relative increase in fluorescence signal in the presence and absence of CB1 
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receptor agonist ACEA. ACEA had no significant effect on fluorescent transmitter 
uptake (N= 6, Mann-Whitney test P>0.05, P= 0.6192; N=6). 
4.3.6. Effect of cannabinoid (CB1) receptor antagonist AM281, on NTUA uptake in 
differentiated PC12 cells 
Cells were pre-incubated with the CB1 receptor agonist ACEA (100nm) for 10mins, 
before exposing cells to the fluorescent false transmitter (1:10) for 60mins. Images 
were taken every 10miutes for 60mins.Vesicles in cells become more as time 
increase (Fig. 27).  
 
Figure 27: Shows fluorescence false transmitter uptake in the differentiated PC12 
cells at different time intervals in the presence of CB1 agonist ACEA (0mins, 30mins 
and at 60mins). Scale bar = 10µm. 
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Figure 28: Shows fluorescence image when PC12 cells were exposed to ACEA and 
AM281 cells at at different time intervals 0mins, 30mins and at 60mins. Scale bar = 
10µm Scale bar = 10µm. 
Cells were pre-incubated with the CB1 receptor agonist ACEA (100nm) plus the 
cannabinoid antagonist AM281 (100nM) for 10mins, before exposing cells to 
fluorescent false transmitter (1:10) for 60mins. Images were taken every 10miutes 
for 60mins (fig. 28). An increase fluorescence signal was detected in both conditions, 
however no significant change was observed in the presence of the CB1 antagonist 
AM281 (fig. 29).  
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Figure 29: Graph showing fluorescence signal in differentiated PC12 cells during 
exposure to ACEA and AM281. Data points are presented as mean ± S.E. Student’s 
unpaired t-test P>0.05; Nc= 5-7 cells. 
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4.4. Plate reader 
. Cells were plated down in and differentiated in a 96 well plate. On the day of 
experiment, cells were exposed to 5 conditions the fluorescent false transmitter 
(1:10) was added to each well with a cells, either in the presence of, GBR (100nM), 
ACEA (100nM), AM281 (100nM) or AM281 + ACEA. The well with just the 
fluorescent false transmitter (1:10) acted as the control and each condition was 
repeated in 5wells. After analysis, a gradual fall in signal was observed for all wells. 
Figure 30 shows the graph representation for the average reading gotten from the 
control wells. Result showed that, uptake of the fluorescent false transmitter wasn’t 
achieved by the cells using the plate reader technique. All conditions showed no 
increase in fluorescence signal with time and reading weren’t consistent (See 
Appendix). 
 
Figure 30: Shows fluorescence signal of PC12cells in the presence of the false 
transmitter using a fluorescence plate reader 
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4.5. Quantitative real time PCR (q-PCR): 
 
Figure 31: Graphical representation of q-PCR analysis carried out showing PCR cycle 
number for each sample. Log fold dilution of Cnr1 in triplicate wells for each sample. 
The green line running across indicates the threshold which remained the same in all 
q-PCR runs. 
The quantitative level of CB1 receptor gene (Cnr1) expression was measured in 
PC12 cells which were differentiated in vitro for seven days and also as a positive 
control in slice of rat brain (both cortex and brain stem). Each sample was measured 
in triplicate wells and for ensuring reproducibility q-PCR was performed on three 
different days. Figure 31 shows the average relative expression of the CB1 receptor 
(Cnr1) gene in each sample.Cnr1 was detected in all brain samples. In comparison it 
was detected in a low quantity in PC12 cells. This shows the relative quantity in all 
samples when compared to the control (GAPDH) are approximately equal for 
example sample  2 is 100 folds higher than sample 1 and sample C1 is 10 fold more 
than sample 2 in both cases. Both samples of PC12 cells tested showed insignificant 
difference in the mRNA expression of the CB1 receptor gene.   
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Figure 32: Chart showing fold change comparing the average relative expression of 
three qPCR runs carried out on the samples. cDNA levels of Cnr1 measured in 
differentiated PC12 cells and rat brain tissue. (Samples: 1- : 8th day differentiated 
PC12 cells; 2:- 7th day differentiated PC12 cells; C1-2:- cortex; B1-2 - Brain stem). 
Also shows fold change in gene relative expression normalized to the control gene 
(GAPDH). Fold change refers to the change in expression level of the Crn1 gene, from 
the final to initial value in each sample. Bars with star (*) are statistically significantly 
(****P<0.0001, **P<0.01 using one way ANOVA) different compared to sample 1. 
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5.0. Discussion 
A link between cannabinoid signalling and the DAT was initially suggested by an 
incidental observation that tetrahydrocannabinol seems to inhibit noradrenaline 
uptake into sympathetic terminals in the mouse vas deferens (Kennard and Brain, 
personal communication). If such a link occurs for the noradrenaline transporter, 
then the question might naturally be asked as to whether the dopamine transporter is 
similarly regulated. 
Abnormalities in brain monoamine transmission are associated with a number of 
neurodegenerative and neuropsychiatric diseases including drug addiction, 
depression and Parkinson’s disease (Manson et al., 2005). DA is linked to most 
neuropsychiatric disorders. DAT is localized at presynaptic sites, where it is vital for 
maintenance of DA storage and for the termination of DA transmission (Jorgensen, 
Nielsen, Peters and Dyhring, 2008). Studying changes in this transporter function 
may facilitate to gain new insights into the mechanisms regulating neurotransmission 
in neuropsychiatric diseases (Petal et al., 2003). Presynaptically, Na+/Cl−-dependent 
transporters play a crucial role in limiting the actions of catecholamine at target 
receptors in both the central and peripheral nervous system (Manson et al., 2005). 
Studies show contribution of these transporters and their regulation to a wide range 
of physiological activities, e.g. cognitive behaviour and autonomic function (Wu et. 
al., 2002). Given their impact on chemical signalling, it is not surprising to learn that 
DAT, as well as other neurotransmitter transporters are themselves subject to 
regulation (Manson et al., 2005; Zahniser and Doolen, 2001). 
Initially studies were conducted using human derived human neuroblastoma, BE(2)-
M17 cells. From the study carried out, these cells showed a steady increase in 
fluorescence after exposure to the fluorescent false transmitter. However, overall 
cells showed a weak and inconsistent uptake of the fluorescent neurotransmitter. 
After failure to improve uptake in these cells, it became necessary to apply the study 
using an alternative cell line. The phaeochromocytoma (PC12) cell line was then 
used to carry out subsequent studies. This cell line originates from a rat adrenal 
chromaffin cells tumour (Fujita et al., 1989; Schimmelpfeng et al., 2004). This cell 
line is useful for neurobiological studies and when differentiated it induces changes 
in the cell resulting particularly in increased characteristics of sympathetic neurons 
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(Das et al., 2004). Results from the undifferentiated PC12 cells showed that the rate 
of uptake of the fluorescent false transmitter was relatively low, but still was greater 
than that seen BE(2)-M17 studies. The uptake was however, sufficiently low that any 
regulation of the transporter might be below detection threshold because of a lack of 
power to distinguish important effects. Therefore, in order to maximize and attain a 
reasonable uptake, the PC12 cells were differentiated in vitro before used in the 
experiments.  
The process of differentiation can be induced in PC12 cells by various factors, which 
includes: nerve growth factor (NGF), cytokines, epidermal growth factor and basic 
fibroblast growth factor (Ohuchi et al., 2002). For the purpose of this study, NGF was 
used to induce neuronal differentiation of PC12 cells. An important feature of PC12 
cells is that they respond to NGF with a dramatic change in phenotype and acquire a 
number of properties and characteristic of sympathetic neurons (Das et al., 2004). 
NGF is a peptide required for the survival and development of sympathetic and 
sensory neurons (Kim et al., 1990). NGF differentiates the cells by acting on the 
TrkA receptors, leading to the sustained activation of the Raf/MEK/MAPK pathway 
(Das et al., 2004) and subsequently to neuronal differentiation (Kao et al., 2001). 
NGF-treated PC12 cells cease proliferation, extend neurites, and become electrically 
excitable (Ohuchi et al., 2002). 
Differentiation of PC12 cells is assessed by quantitative or semi-quantitative 
morphological methods. These methods include measurement of cell size, the 
number of cells possessing neurites, and measurement of neurite length (Das et al., 
2004).These assessment methods can be difficult in large samples of cells. The 
reason for differentiating the cell is to ensure cells were exhibiting characteristics of 
mature neurons which includes neurotransmitter release, membrane excitability and 
exocytosis (Andres et. al., 2013). 
In the present work differentiated cells were seen to develop neurites by the third day 
of NGF treatment, and the cells were used for experiment on the seventh day. The 
uptake of the fluorescent false transmitter in differentiated cells was largely 
increased compared to the undifferentiated ones. Both differentiated and 
undifferentiated cells displayed a time-dependent uptake of the fluorescent false 
transmitter, showing monoamine transporter activity. During 30mins washout, cells 
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were seen to gradually drop fluorescence signal. This result suggests that 
fluourescent false transmitter was indeed taken up into the cells through one of the 
monoamine transporter. Given the known transporters on differentiated PC12 cells 
and NTUA kit used, it was expected that most of the uptake will be through DAT. 
 In order to investigate and determine if uptake of the fluorescent false transmitter 
was through DAT, the cells were pre-incubated in GBR 12909 (100nM). GBR is a 
potent monoamine uptake inhibitor with a high specificity for DAT. GBR is about 2 
folds more potent as an inhibitor of dopamine uptake than that of either 
noradrenaline or serotonin uptake (Melia and Spealman, 1991). In behavioural 
studies, the effect of GBR has been found to mimic those of psychomotor-stimulant 
drugs known to inhibit dopamine uptake, including cocaine and bupropion. Like 
cocaine, it binds to the DAT at the terminal fields of the mesocorticolimbic pathway, 
where it inhibits the reuptake of dopamine leading to an increase in the extracellular 
concentration of dopamine (Melnick et al., 2001). Results from this study showed a 
time-dependent accumulation of fluorescence false transmitter in the differentiated 
PC12 cells, both in the presence and absence of the inhibitor, GBR 12909. However, 
when fluorescence uptake is being compared to the control, it shows a 70% 
reduction in fluorescence signal in the presence of GBR 12909 (Fig. 17). This shows 
GBR is possibly blocking or inhibiting DA uptake by DAT. The uptake of false 
transmitter in a preliminary study from our laboratory showed that GBR12909 
inhibited the fluorescent false transmitter study but in the presence of NAd blocker 
desipramine, the uptake was not affected in undifferentiated PC12 cells (Sideway et 
al., 2011).  
NAd transporter is also a member of the NA+/-Cl transporter family (Blakely et al., 
1994). Most NAd inhibitors particularly drugs of abuse and tricyclic antidepressant 
also act on NE, AD and DA transporters, particularly drugs of abuse and tricyclic 
antidepressants (Parker et al., 2010). In other to investigate the specificity of 
fluorescent false transmitter, cells were exposed to desipramine (1µM) and uptake of 
the fluorescent false transmitter in the presence of desipramine was carried out (Fig. 
21 and 22). Cells exhibited a significant decrease in NTUA uptake in the presence of 
desipramine. Desipramine is an antidepressant, which like many works by inhibiting 
NAd transporter. Selective blockers of the NAd transporter have been hypothesized 
to also inhibit DA uptake in some parts of the brain, mainly prefrontal cortex. 
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Evidence from Moron et al. (2002) suggests that DA uptake depend on DAT in 
nucleus accumbens and caudate areas of the brain, but dependent on NET in 
prefrontal cortex (Moron et al., 2002). It is therefore possible that the dopamine 
transporter substrate in NTUA was also transported into the cells through 
noradrenalin transporter, hence the reduction in fluorescence signals in the presence 
of desipramine. 
In order to understand whether cannabinoids have an effect on DA signalling in the 
brain, a specific CB1 receptors agonist, ACEA was used in the study. The effect of 
cannabinoids on synaptic function consists of inhibition of the release of a variety of 
neurotransmitters and also the inhibition of electrical activity by a depolarisation. In 
all experiments carried out (N=6), there was no significant effect in fluorescence 
uptake in the presence of the CB1 agonist. This suggests that either that: 
 CB1 receptor activation has no effect on DAT function, or 
 CB1 receptors are not sufficiently expressed in these cells, or 
 the agonist was ineffective in these cells. 
In order to determine whether endocannabinoid activation might regulate DAT 
function at rest (indirectly testing hypothesis 3.) the effect of the DAT antagonist 
AM291 alone was determined. The antagonist AM281 had no significant effect on 
fluorescent false transmitter uptake. It therefore would be requisite to investigate if 
PC12 cells express CB1 receptor seeing as it is the predominant cannabinoid found 
in the central nervous system and is of importance to this present study. 
CB1 receptors have been reported to be highly present in the central nervous system 
where it plays a part in synapse density, reward and behaviour (Pertwee, 1997; 
Takahashi and Castillo, 2006). However the present study is based on the effect of 
cannabinoid on dopamine transporter in PC12 cells. Molderings et al. (2002) carried 
out a study aimed to examine CB1 receptor expression in PC12 cells using PCR and 
radio ligand binding techniques. Using primers for the rat CB1 receptor gene, they 
showed that undifferentiated PC12 cells did not express detectable amounts of CB1 
receptors. In conclusion, undifferentiated PC12 cells were not endowed with 
CB1 cannabinoid receptors (Molderings et al., 2002). Absence of CB1 receptors in 
PC12 cells was also reported by other studies, (Marsicano et al., 2002). However, it 
is not clear whether or not differentiated PC12 cells express the CB1 receptor.  
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In the present work of CB1 receptor was investigated using q-PCR method. The q-
PCR results indicate that the gene encoding the CB1 receptor underwent 
transcription in all samples tested. However, there was a higher transcription rate in 
the cortex than in the other samples tested. CB1 receptors have been shown through 
histology studies to be extensively mapped in rodent brain, with the rat cortex 
showing a more prominent pattern of CB1 receptor expression (Tsou et al., 1998). 
THC can induce apoptosis in cultured neuronal cells. This apoptotic effect is exerted 
through THC binding to and activating the CB1 receptor, which are said to be linked 
to stress activated protein kinase. However in the presence of THC this process of 
apoptotic cell death was blocked when the CB1 antagonist AM251 was exposed to 
the cells (Downer et al., 2003). Same study was carried out using anandamide (7 µM 
-10µM). PC12 cells were incubated with different concentrations of ananadamide 
and massive cell death was recorded with the batch incubated with higher 
concentration of anadamide. Anandamide exerts most of its effect by activating the 
CB1 receptor in the brain (Sarker et al., 2000). The finding that the CB1 receptor 
antagonist inhibits apoptosis in neuronal cells induced by THC and anandamide 
supports the finding from this present study that PC12 cells can expresses the CB1 
receptor.  Surprisingly the PC12 cells differentiated to day 8th showed a lower 
detection of the Cnr1 gene. While this might suggest that the more prolonged 
differentiation results in a loss of certain function, it is also possible that this is due to 
variability in the expression amongst cell populations in different experiments. It was 
also observed that cells with early passage (p= <11) had better uptake of fluorescent 
false transmitter, whereas with increasing passage a noticeable drop in uptake ability 
rate was observed (although this was not formally quantified). 
The study using the fluorescence plate reader was performed in order to establish a 
more rapid method for testing cellular uptake and regulation. However, these 
experiments were unable to show, under control conditions, uptake of NTUA in the 
differentiated PC12 cells. Unsurprisingly, therefore in all conditions of drug 
incubation with the cells, there was no appreciable effect. This possibly was due to 
the fact the plate reader used didn’t have the optimal excitable wavelength required 
for NTUA, which is 405nm. Alternatively, the cell density needed to be increased, 
from the 50,000cells per well plate for the differentiation in this study. However the 
differentiation process requires cells to be incubated in NGF for 7days. NGF media 
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changed every day. Cells density may have been lowered due to this process of 
multiple solution changes: with each solution change some cells can be lost due to 
detachment.  
In conclusion the NTUA is a useful method for detecting neurotransmitter transporter 
activity in cells using microscopy-based approaches, but the sensitivity is too low for 
routine use in plate reader experiments with differentiated PC12 cells using the 
current experimental protocol. The cannabinoid agonist used in this study showed no 
significant effect on fluorescence intensity in differentiated PC12 cells, despite the 
presence of the receptor (as assessed with q-PCR). The low expression of the Cnr1 
gene detected from q-PCR in this cell type could be the reason. Alternatively, it may 
be that CB1 receptor activation has no effect on DAT function. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                               MSC Pharmacology                             
61 
 
6.0. Future Work 
Against the result of the present study, the following points for the future study can 
be considered: 
 Studies involving cannabinoid should be carried out using cell type other than 
PC12 cells, that express high levels of the cannabinoid receptors such as the 
cells from mouse neuroblastoma N1E-115cells and cerebellar cell culture. 
Study should also be carried out using a second agonist, such as THC, in 
order to confirm this finding.  
 In addition to q-PCR other techniques such as immune precipitation combined 
with Western blotting should be undertaken to demonstrate the receptors are 
expressed.  
 
Further refinement of the plate reader approach, including an increase in the plating 
density and optimisation of the excitation wavelength, would be useful in order to 
increase the sensitivity of this method, which has the potential to greatly increase the 
speed with which functional changes in DAT rate can be studied. 
For purpose of this study it would be further studies would be required, particularly 
focusing on the signal transduction pathways linking DAT and CB receptors. Such an 
interaction would then be explored in a tissue preparation, such as the autonomic 
innervation of the vasculature (in Prof Janice Marshall’s laboratory). Central 
dopaminergic signaling could also be investigated in rat brain slices containing fields 
of DAT-expressing terminals. 
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7.0. APPENDIX 
Table 2: Raw data of study carried out on NTUA uptake in BE-(2)-M17 cells. 
Table 2A 
Time(mins) NTUA (1:10) GBR 100nM S.E NTUA S.E GBR 
0 0 0 0.230161356 0.077963667 
10 -0.4216 0.30175 0.252803184 0.11195969 
20 0.774 0.4795 0.303845767 0.084846266 
30 1.4512 0.672 0.370418075 0.070587219 
40 1.7842 0.877 0.422228818 0.093875213 
50 2.191 0.95275 0.443204947 0.119651694 
60 2.4872 0.9835 0.465769712 0.087438868 
*P = 0.371 
Table 2B 
Time(mins) NTUA GBR 
0 0 0 
10 -3.16367 -1.9386 
20 3.846833 -0.461 
30 4.598097 2.1806 
40 5.596333 -0.5452 
50 9.450667 -0.5778 
60 12.7555 -0.346 
P = 0.050397 
Table 2C 
Time (mins) NTUA GBR 
0 0 0 
10 -13.2193 -11.7155 
20 -13.4458 -13.8903 
30 -9.05975 -2.967 
40 9.3875 1.39025 
50 12.45975 5.54475 
60 18.919 10.878 
P=0.713924 
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Table 2D 
TIME(mins) NTUA GBR (100nM) 
0 0 0 
10 -10.803 -15.703 
20 -8.6222 -17.7365 
30 -4.4254 -14.114 
40 -4.4254 -8.8515 
50 3.3876 -3.2805 
60 14.625 -4.0475 
P= 0.0922 
Table 2E 
Time(mins) NTUA GBR 100nM 
0 -0.06717 0 
10 1.958167 0.86625 
20 4.686 0.842 
30 5.5045 1.0025 
40 6.866667 1.417 
50 7.5285 1.5855 
60 9.203 1.653 
*P=0.01585 
 
 
 
 
 
 
 
 
 
 
 
Table 3: NTUA uptake in PC12 cells over time. 
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Table 3A: Change in fluorescence signal in PC12 cells over time. 70-90mins were 
washout periods. 
Time(mins) 
Undiffrenciated 
cells 
Differentiated 
cells 
S.E 
undifferentiated 
cells 
S.E Differentiated 
cells 
0 0 0 5.314534397 8.124044877 
10 14.669 56.717 8.481444903 1.613898592 
20 38.1205 126.0023333 14.71918349 12.93489967 
30 60.1325 187.4393333 19.69513272 23.15497634 
40 81.43525 267.1586667 26.72478945 26.25348219 
50 106.5865 338.5546667 32.78841239 39.82046711 
60 116.931 396.6853333 31.86517845 52.30691478 
70 120.04 447.257 29.94988522 56.47672881 
80 102.143 495.5353333 22.90208038 67.37933121 
90 79.41875 446.0898333 18.08972981 58.40110051 
*P= 0.00514 
Table 3B 
Time(minutes) Undifferentiated cells Differentiated cells 
0 14.67457 -18.6155 
10 17.80786 20.07716667 
20 23.80429 33.3755 
30 27.68914 47.90333333 
40 30.05214 54.39366667 
50 33.71257 65.723 
60 34.067 78.87316667 
P= 0.296 
 
 
 
 
 
 
Table 3C 
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Time(mins) Undifferntiated cells Differntiated cells 
0 0 0 
10 26.31683333 53.714 
20 41.35416667 121.4925 
30 58.2925 188.059 
40 73.427 242.228 
50 79.16333333 296.87325 
60 92.70866667 341.37075 
*P=0.0400 
Table 3D: 
Time(mins) Undiffrenciated cells Differentiated cells 
0 0 0 
10 14.669 56.717 
20 38.1205 126.0023333 
30 60.1325 187.4393333 
40 81.43525 267.1586667 
50 106.5865 338.5546667 
60 116.931 396.6853333 
*P= 0 .0499 
Table 3E 
Time(mins) Undiffrenciated cells Differentiated cells 
0 0 0 
10 3.133285714 81.4624 
20 9.129714286 202.0868 
30 13.01457143 316.9812 
40 15.37757143 214.4313 
50 19.038 284.364 
60 19.39242857 384.56 
*P= 0.0075 
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Table 3F 
Time(mins) Undiffrenciated cells Differentiated cells 
0 0 0 
10 41.35416667 874.49 
20 59.61728571 1325.4362 
30 69.64842857 1533.3926 
40 83.39314286 1694.8558 
50 95.83528571 1795.6158 
60 103.4682857 1894.2974 
*P= 0 .003 
Table 4:Change in fluorescence signal in PC12 cells over time in presence and 
absence of GBR 
Table 4a: Raw data showing Change in fluorescence signal in PC12 cells over time in 
presence and absence of GBR (100nM). 70-90mins were washout periods. 
*P= 0.00028 
 
 
 
 
 
 
 
Time(mins) NTUA NTUA+GBR(100nM) SE-NTUA SE-GBR 
0 0 0 6.05931824 12.49445 
10 96.4308 3.419333333 16.7834994 15.9467 
20 112.181 4.530333333 19.254987 18.19094 
30 125.4372 25.7175 22.4271069 24.05137 
40 165.1378 35.766 25.7327549 26.39442 
50 186.6358 47.09766667 27.9564775 30.80649 
60 207.634 64.46683333 29.5970412 35.83661 
70 195.4214 61.85533333 27.1877483 38.11537 
80 189.1864 59.51866667 26.0783508 39.28455 
90 178.3462 50.54516667 28.2224972 35.22564 
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Table 4B 
Time(mins) NTUA NTUA + GBR(100nM) 
0 0 0 
10 212.65 -16.719 
20 260.29 -9.14825 
30 321.32 9.581 
40 414.81 33.1725 
50 512.35 65.3435 
60 539.48 96.521 
*P=0.0052 
Table 4C 
Time(mins) NTUA NTUA + GBR(100nM) 
0 0 0 
10 132.4215 19.2038 
20 269.2463 66.1686 
30 411.0475 124.4892 
40 533.2325 187.602 
50 632.2195 246.8254 
60 739.3613 307.9328 
P=0.0518 
Table 4D 
Time (mins) NTUA NTUA +GBR(100nM) 
0 0 0 
10 29.88617 0.85925 
20 41.84983 2.19425 
30 79.93017 4.34825 
40 99.75033 13.0645 
50 115.5332 16.58575 
60 132.6807 18.4425 
*P=0.0134 
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Table 4E 
Time(mins) NTUA NTUA + GBR(100nM) 
0 0 0 
10 22.30066667 47.1675 
20 22.30066667 31.34525 
30 36.21866667 17.2145 
40 42.02533333 33.51225 
50 40.815 23.653 
60 44.42266667 13.091 
*P=0.486 
Table 5: uptake of NTUA IN differentiated PC12 cells in the presence and 
absence of Desipramine (IµM) 
Table 5A 
 
 
 
 
 
P=0.12 
Table 5B 
Time (mins) NTUA Desipramine 1µM SE NTUA SE Des 
     
0 0 0 13.119145 5.780581 
10 40.29 7.85925 16.02011 6.905194 
20 52.3306 15.69425 13.987291 9.611358 
30 135.903 26.3605 27.823327 6.945371 
40 151.2046 35.5645 28.604164 12.55151 
50 174.1746 46.58575 30.796434 10.19736 
60 241.2186 58.4425 44.394737 8.609224 
*P=0.04 
 
Time(mins) NTUA(1:10) 
Desipramine 
(1µM) S.E NTUA 
S.E 
Desipramine 
0 0 0 5.176066718 9.814145929 
10 17.33333333 8.571428571 4.911720676 11.75907282 
20 28.33333333 12.78571429 10.25304833 12.08534466 
30 39.5 18.71428571 19.85048278 14.76629056 
40 52.66666667 24.5 23.23879658 17.93085236 
50 72.33333333 32.64285714 19.94993734 18.33009407 
60 102.8333333 40.85714286 18.97695971 21.02234383 
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Table 5C 
Time(mins) NTUA Desipramine 
0 0 0 
10 26.55783 18.2425 
20 30.06883 25.992 
30 38.91867 34.89066667 
40 50.765 44.16516667 
50 57.81283 59.54583333 
60 66.23017 74.183 
P=0.88 
Table 5D 
Time (mins) NTUA Desipramine 
0 0 0 
10 17.29125 6.770666667 
20 36.906 12.77933333 
30 44.5585 17.08233333 
40 54.96575 25.401 
50 73.76675 38.71433333 
60 92.6955 47.08233333 
P=0.10 
Table 5E 
Time(mins) NTUA Desipramine(µM) 
0 0 0 
10 28.7375 1.9806 
20 47.39783 32.0944 
30 58.6165 37.8074 
40 75.42433 43.5638 
50 92.73683 49.0148 
60 121.1235 50.3614 
P= 0.12 
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Table 6: NTUA uptake in differentiated PC12 cells in the presence ACEA 
(100nM) 
Table 6A 
Time (mins) NTUA (1:10) ACEA (100nM) S.E NTUA S.E ACEA 
0 0 0 18.50786 11.71715 
10 16.98867 13.61425 27.06158 11.20988 
20 49.29333 38.32775 24.14223 18.61513 
30 85.50933 63.31775 26.62188 29.21019 
40 114.4513 93.97875 29.06906 43.10169 
50 142.4477 115.8753 33.13627 50.4989 
60 178.4083 140.3658 40.55381 62.00121 
P=0.604 
Table 6B 
Time (mins) NTUA ACEA(100nM) 
0 0 0 
10 16.353 9.856 
20 50.462 24.592 
30 89.200 37.649 
40 134.081 53.472 
50 218.507 73.629 
60 239.006 96.333 
P=0.130 
Table 6C 
Time(mins) NTUA ACEA(100nM) 
0 0 0 
10 1.415625 44.41167 
20 9.69075 76.13083 
30 19.123 118.4398 
40 43.7465 160.3723 
50 55.1085 190.1902 
60 68.97363 227.3113 
*P= 0.029 
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Table 6D 
Time (mins) NTUA ACEA (100nM) 
0 0 0 
10 10.7573333 179.1698 
20 16.9435 128.2211 
30 34.1221667 147.1823 
40 44.1918333 160.4321 
50 55.9386667 178.7635 
60 64.113 206.0888 
*P= 0.004 
Table 6E 
Time(mins) NTUA ACEA (100nM) 
0 0 0 
10 17.14329 0.6414 
20 34.31857 8.8622 
30 68.56114 13.6642 
40 97.003 14.9426 
50 127.131 23.239 
60 154.6641 40.4266 
*P= 0.041 
Table 6F 
Time  NTUA ACEA(100nM) 
0 0 0 
10 30.28129 40.30986 
20 62.278 -2.55114 
30 85.62971 110.3696 
40 100.5724 127.533 
50 128.0826 147.0914 
60 136.3104 177.614 
P=0.813 
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Table 7: NTUA uptake on PC12 cells in the presence of ACEA in the presence 
CB1 antagonist AM281(100nM) 
Table 7A 
TIME (mins) ACEA(100nM) AM281(100nM) S.E ACEA S.E AM281 
0 0 0 5.4556027 10.904109 
10 15.97635 19.4689 11.187659 11.177475 
20 36.9639 39.98643 15.489146 10.794005 
30 62.54781 48.54617 18.901194 10.878564 
40 93.09558 74.25403 22.746181 11.648734 
50 151.0478 91.0452 26.313502 13.215047 
60 180.0846 113.7004 27.525036 13.647139 
*P=0.483 
Table 7B 
TIME (mins) ACEA(100nM) AM281(100nM) 
0 0 0 
10 32.39157 13.18329 
20 57.35971 27.93971 
30 95.79514 49.15571 
40 149.2656 64.05686 
50 200.944 88.64057 
60 255.9107 167.85214 
P=0.053 
Table 7C 
TIME (mins) ACEA(100nM) AM281(100nM) 
0 0 0 
10 18.07 11.2098 
20 32.15903 27.8204 
30 48.95321 46.71136 
40 74.51171 78.65447 
50 124.0438 86.982 
60 166.0039 100.90376 
P=0.569 
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Table 8: NTUA uptake using plate reader 
Raw data of Studies carried out on fluorescence uptake in differentiated PC12 cells 
pre-incubated with NTUA, GBR, CB1 agonist ACEA and CB1 antagonist AM281. 
Time(mins) NTUA(1:10) GBR(100nM) ACEA(100nM) AM281 + ACEA AM281(100nM) 
0 13374.8 11350.2 12901.2 12881.8 11389.2 
5 13039.4 11106.6 12629 12604.2 11139.2 
10 12891.2 10982.6 12489.6 12474.2 10990.4 
15 12782.2 10893.6 12381.6 12360.8 10887.8 
20 12737.4 10826.2 12341.4 12302.6 10830.8 
25 12692 10795.6 12274.6 12243.6 10801.2 
30 12646 10767.6 12261.4 12212.4 10758.2 
 
Table 9: q-PCR analysis showing the relative quantities 
Table 9A:  Raw data from q-PCR analysis, showing the relative quantities of the Cnr1 
gene in the different samples. (N= 3).  
Samples 
Relative Quantity 
(RQ) RQ2 RQ3 Avg RQ S.E 
1 1 1 1 1 0 
2 132.727 120.873 120.145 124.5817 4.078085 
C1 1158.044 1439.799 1353.975 1317.273 83.38019 
C2 832.427 1098.593 1147.978 1026.333 97.99537 
B1 387.395 266.883 394.374 349.5507 41.3829 
B2 232.589 589.368 314.784 378.9137 107.8692 
Blank 0 0 0 0 0 
 
Table 9B : Raw data from q-PCR analysis, showing the relative expression of Cnr1 
normalised to GAPDH. (N=3) 
Samples Rq1 Rq2 Rq3 Av. Rq 
1 5.32799E-05 1.64453E-05 2.02045E-05 2.99766E-05 
2 0.00337675 0.003290776 0.0022092 0.002958909 
C1 0.029377018 0.038701241 0.024665015 0.030914425 
C2 0.021160081 0.029177352 0.021101791 0.023813074 
B1 0.009926613 0.007132932 0.007233322 0.008097623 
B2 0.005979217 0.015664504 0.005712908 0.009118876 
Blank 0 0 0 0 
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Table 9C : Raw data from q-PCR analysis, showing the number of cycles cycle 
number of the Cnr1 gene in the different samples. (N=3). 
Samples Ct Ct2 Ct3 Avg Ct 
1 39.03133 38.712 38.019 38.58744 
2 32.77267 33.195 32.861 32.94289 
C1 31.16467 30.886 30.999 31.01656 
C2 32.09233 32.097 31.945 32.04478 
B1 32.68133 31.255 32.942 32.29278 
B2 31.424 32.065 31.041 31.51 
Blank 0 0 0 0 
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